Video

AACE 21st Annual Scientific and Clinical Congress Slideshow

Author(s):

Onclive Team

Photos taken from the AACE 21st Annual Scientific and Clinical Congress held at the Pennsylvania Convention Center, from May 23-27, 2012.

Photos taken from the American Association of Clinical Endocrinologists (AACE) 21st Annual Scientific and Clinical Congress held at the Pennsylvania Convention Center, from May 23-27, 2012.

<<<

View more from the 2012 AACE Conference

Related Videos
Victor Moreno, MD, PhD
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Ashraf Z. Badros, MBCHB
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.
Related Content
Chronic Lymphocytic Leukemia
November 13th 2024

Piecing Together the Proper BTK Usage in CLL

Jennifer Amengual, MD, Herbert Irving Assistant Professor of Medicine, Division of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center
November 13th 2024

Real-World Experience With CAR T Varies From Trials in DLBCL

LASZLO – stock.adobe.com
November 13th 2024

TAB-Follicular Lymphoma

RP1 Plus Nivolumab in Advanced Melanoma | Image Credit: © ReisMedia - stock.adobe.com
November 11th 2024

RP1 Plus Nivolumab Is Active, Safe in Advanced Melanoma After Progression on Anti–PD-1 Therapy

IMA203 in Melanoma
November 11th 2024

IMA203 Produces Responses in Heavily Pretreated Advanced Melanoma, Other Solid Tumors

James L. Gulley, MD, PhD
November 11th 2024

Invikafusp Alfa Demonstrates Single-Agent Activity in PD-(L)1–Resistant Solid Tumors